| Pharmaceutical Information |
| Drug Name |
Ezogabine |
| Drug ID |
BADD_D00865 |
| Description |
Ezogabine (D23129) is a close structural analog of the centrally acting analgesic flupitrine. It is a neuronal potassium channel opener being developed as a first-in-class antiepileptic drug (AED) and is currently being studied in Phase 3 trials as an adjunctive treatment for partial-onset seizures in adult patients with refractory epilepsy. FDA approved in June 10, 2011 under the name of ezogabine. |
| Indications and Usage |
Adjuvant treatment of partial-onset seizures. |
| Marketing Status |
approved; investigational |
| ATC Code |
N03AX21 |
| DrugBank ID |
DB04953
|
| KEGG ID |
D09569
|
| MeSH ID |
C101866
|
| PubChem ID |
121892
|
| TTD Drug ID |
D0X7GL
|
| NDC Product Code |
Not Available |
| UNII |
12G01I6BBU
|
| Synonyms |
ezogabine | retigabine | N-(2-amino-4-(4-fluorobenzylamino)phenyl)carbamic acid ethyl ester | D 20443 | D-20443 | Potiga | D 23129 | D-23129 | ethyl N-(2-amino-4-(4-fluorobenzylamino)phenyl)carbamate hydrochloride |
|
| Chemical Information |
| Molecular Formula |
C16H18FN3O2 |
| CAS Registry Number |
150812-12-7 |
| SMILES |
CCOC(=O)NC1=C(C=C(C=C1)NCC2=CC=C(C=C2)F)N |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
|
|
|
